Cargando…

Quantifying infection risks in incompatible living donor kidney transplant recipients

Desensitization has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but added immunomodulation might put patients at increased risk of infections. We studied 475 recipients from our center from 2010 to 2015, categorized by desensitization intensity: none/com...

Descripción completa

Detalles Bibliográficos
Autores principales: Avery, Robin K., Motter, Jennifer D., Jackson, Kyle R., Montgomery, Robert A., Massie, Allan B., Kraus, Edward S., Marr, Kieren A., Lonze, Bonnie E., Alachkar, Nada, Holechek, Mary J., Ostrander, Darin, Desai, Niraj, Waldram, Madeleine M., Shoham, Shmuel, Steinke, Seema Mehta, Subramanian, Aruna, Hiller, Janet M., Langlee, Julie, Young, Sheila, Segev, Dorry L., Garonzik Wang, Jacqueline M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972996/
https://www.ncbi.nlm.nih.gov/pubmed/32949093
http://dx.doi.org/10.1111/ajt.16316
_version_ 1783666753540194304
author Avery, Robin K.
Motter, Jennifer D.
Jackson, Kyle R.
Montgomery, Robert A.
Massie, Allan B.
Kraus, Edward S.
Marr, Kieren A.
Lonze, Bonnie E.
Alachkar, Nada
Holechek, Mary J.
Ostrander, Darin
Desai, Niraj
Waldram, Madeleine M.
Shoham, Shmuel
Steinke, Seema Mehta
Subramanian, Aruna
Hiller, Janet M.
Langlee, Julie
Young, Sheila
Segev, Dorry L.
Garonzik Wang, Jacqueline M.
author_facet Avery, Robin K.
Motter, Jennifer D.
Jackson, Kyle R.
Montgomery, Robert A.
Massie, Allan B.
Kraus, Edward S.
Marr, Kieren A.
Lonze, Bonnie E.
Alachkar, Nada
Holechek, Mary J.
Ostrander, Darin
Desai, Niraj
Waldram, Madeleine M.
Shoham, Shmuel
Steinke, Seema Mehta
Subramanian, Aruna
Hiller, Janet M.
Langlee, Julie
Young, Sheila
Segev, Dorry L.
Garonzik Wang, Jacqueline M.
author_sort Avery, Robin K.
collection PubMed
description Desensitization has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but added immunomodulation might put patients at increased risk of infections. We studied 475 recipients from our center from 2010 to 2015, categorized by desensitization intensity: none/compatible (n = 260), low (0‐4 plasmaphereses, n = 47), moderate (5‐9, n = 74), and high (≥10, n = 94). The 1‐year cumulative incidence of infection was 50.1%, 49.8%, 66.0%, and 73.5% for recipients who received none, low, moderate, and high‐intensity desensitization (P < .001). The most common infections were UTI (33.5% of ILDKT vs. 21.5% compatible), opportunistic (21.9% vs. 10.8%), and bloodstream (19.1% vs. 5.4%) (P < .001). In weighted models, a trend toward increased risk was seen in low (wIRR = (0.77)1.40(2.56),P = .3) and moderately (wIRR = (0.88)1.35(2.06),P = .2) desensitized recipients, with a statistically significant 2.22‐fold (wIRR = (1.33)2.22(3.72),P = .002) increased risk in highly desensitized recipients. Recipients with ≥4 infections were at higher risk of prolonged hospitalization (wIRR = (2.62)3.57(4.88), P < .001) and death‐censored graft loss (wHR = (1.15)4.01(13.95),P = .03). Post–KT infections are more common in desensitized ILDKT recipients. A subset of highly desensitized patients is at ultra‐high risk for infections. Strategies should be designed to protect patients from the morbidity of recurrent infections, and to extend the survival benefit of ILDKT across the spectrum of recipients.
format Online
Article
Text
id pubmed-7972996
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79729962021-04-19 Quantifying infection risks in incompatible living donor kidney transplant recipients Avery, Robin K. Motter, Jennifer D. Jackson, Kyle R. Montgomery, Robert A. Massie, Allan B. Kraus, Edward S. Marr, Kieren A. Lonze, Bonnie E. Alachkar, Nada Holechek, Mary J. Ostrander, Darin Desai, Niraj Waldram, Madeleine M. Shoham, Shmuel Steinke, Seema Mehta Subramanian, Aruna Hiller, Janet M. Langlee, Julie Young, Sheila Segev, Dorry L. Garonzik Wang, Jacqueline M. Am J Transplant ORIGINAL ARTICLES Desensitization has enabled incompatible living donor kidney transplantation (ILDKT) across HLA/ABO barriers, but added immunomodulation might put patients at increased risk of infections. We studied 475 recipients from our center from 2010 to 2015, categorized by desensitization intensity: none/compatible (n = 260), low (0‐4 plasmaphereses, n = 47), moderate (5‐9, n = 74), and high (≥10, n = 94). The 1‐year cumulative incidence of infection was 50.1%, 49.8%, 66.0%, and 73.5% for recipients who received none, low, moderate, and high‐intensity desensitization (P < .001). The most common infections were UTI (33.5% of ILDKT vs. 21.5% compatible), opportunistic (21.9% vs. 10.8%), and bloodstream (19.1% vs. 5.4%) (P < .001). In weighted models, a trend toward increased risk was seen in low (wIRR = (0.77)1.40(2.56),P = .3) and moderately (wIRR = (0.88)1.35(2.06),P = .2) desensitized recipients, with a statistically significant 2.22‐fold (wIRR = (1.33)2.22(3.72),P = .002) increased risk in highly desensitized recipients. Recipients with ≥4 infections were at higher risk of prolonged hospitalization (wIRR = (2.62)3.57(4.88), P < .001) and death‐censored graft loss (wHR = (1.15)4.01(13.95),P = .03). Post–KT infections are more common in desensitized ILDKT recipients. A subset of highly desensitized patients is at ultra‐high risk for infections. Strategies should be designed to protect patients from the morbidity of recurrent infections, and to extend the survival benefit of ILDKT across the spectrum of recipients. John Wiley and Sons Inc. 2020-10-25 2021-04 /pmc/articles/PMC7972996/ /pubmed/32949093 http://dx.doi.org/10.1111/ajt.16316 Text en © 2020 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle ORIGINAL ARTICLES
Avery, Robin K.
Motter, Jennifer D.
Jackson, Kyle R.
Montgomery, Robert A.
Massie, Allan B.
Kraus, Edward S.
Marr, Kieren A.
Lonze, Bonnie E.
Alachkar, Nada
Holechek, Mary J.
Ostrander, Darin
Desai, Niraj
Waldram, Madeleine M.
Shoham, Shmuel
Steinke, Seema Mehta
Subramanian, Aruna
Hiller, Janet M.
Langlee, Julie
Young, Sheila
Segev, Dorry L.
Garonzik Wang, Jacqueline M.
Quantifying infection risks in incompatible living donor kidney transplant recipients
title Quantifying infection risks in incompatible living donor kidney transplant recipients
title_full Quantifying infection risks in incompatible living donor kidney transplant recipients
title_fullStr Quantifying infection risks in incompatible living donor kidney transplant recipients
title_full_unstemmed Quantifying infection risks in incompatible living donor kidney transplant recipients
title_short Quantifying infection risks in incompatible living donor kidney transplant recipients
title_sort quantifying infection risks in incompatible living donor kidney transplant recipients
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972996/
https://www.ncbi.nlm.nih.gov/pubmed/32949093
http://dx.doi.org/10.1111/ajt.16316
work_keys_str_mv AT averyrobink quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT motterjenniferd quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT jacksonkyler quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT montgomeryroberta quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT massieallanb quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT krausedwards quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT marrkierena quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT lonzebonniee quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT alachkarnada quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT holechekmaryj quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT ostranderdarin quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT desainiraj quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT waldrammadeleinem quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT shohamshmuel quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT steinkeseemamehta quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT subramanianaruna quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT hillerjanetm quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT langleejulie quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT youngsheila quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT segevdorryl quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients
AT garonzikwangjacquelinem quantifyinginfectionrisksinincompatiblelivingdonorkidneytransplantrecipients